Xylometazoline

Xylometazoline

Clinical data
ATC code	R01AA07 (WHO) S01GA03 (WHO)
Identifiers
IUPAC name 2-((4-(1,1-dimethylethyl)-2,6- dimethylphenyl)methyl)-4,5-dihydro- 1H-imidazole (9CI)
CAS Number	526-36-3
PubChem CID	5709
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C16H24N2
Molar mass	244.38

WikiDoc Resources for Xylometazoline
Articles
Most recent articles on Xylometazoline Most cited articles on Xylometazoline Review articles on Xylometazoline Articles on Xylometazoline in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Xylometazoline Images of Xylometazoline Photos of Xylometazoline Podcasts & MP3s on Xylometazoline Videos on Xylometazoline
Evidence Based Medicine
Cochrane Collaboration on Xylometazoline Bandolier on Xylometazoline TRIP on Xylometazoline
Clinical Trials
Ongoing Trials on Xylometazoline at Clinical Trials.gov Trial results on Xylometazoline Clinical Trials on Xylometazoline at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Xylometazoline NICE Guidance on Xylometazoline NHS PRODIGY Guidance FDA on Xylometazoline CDC on Xylometazoline
Books
Books on Xylometazoline
News
Xylometazoline in the news Be alerted to news on Xylometazoline News trends on Xylometazoline
Commentary
Blogs on Xylometazoline
Definitions
Definitions of Xylometazoline
Patient Resources / Community
Patient resources on Xylometazoline Discussion groups on Xylometazoline Patient Handouts on Xylometazoline Directions to Hospitals Treating Xylometazoline Risk calculators and risk factors for Xylometazoline
Healthcare Provider Resources
Symptoms of Xylometazoline Causes & Risk Factors for Xylometazoline Diagnostic studies for Xylometazoline Treatment of Xylometazoline
Continuing Medical Education (CME)
CME Programs on Xylometazoline
International
Xylometazoline en Espanol Xylometazoline en Francais
Business
Xylometazoline in the Marketplace Patents on Xylometazoline
Experimental / Informatics
List of terms related to Xylometazoline

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Xylometazoline (Neo-Rinoleina®; Novorin®; Olynth®; Otriven®; Otrivin®; Otrivine®; Xymelin®) is a topical decongestant that is directly dosed into the nose, either as a spray or as drops.

Xylometazoline is marketed under the brand names Otrivine or Otrivin, with the standard adult dose being 0.1% w/v xylometazoline. The dose for children under 12 is 0.05%.

The drug works by constricting the blood vessels in the nose. The vasoconstriction means that there is less pressure in the capillaries and less water can filter out, thus less discharge is made. (If the colour of the nasal passage is observed, it is visibly paler after dosage.)

Xylometazoline is designed to mimic the molecular shape of adrenaline meaning that it binds to the same cell receptors adrenaline does. For this reason, it should not be used by people with high blood pressure, or other heart problems. (It acts mainly on alpha-adrenergic receptors.)

Unfortunately the vessels become resistant to the drug after prolonged dosing. The number of receptors decreases, and when the administration of the drug is ceased, chronic congestion can occur; this is called rhinitis medicamentosa, commonly referred to as rebound congestion. Moreover long-term overdosing can cause degenerative changes in nasal mucous membranes that pose another health problem.

Template:SIB bg:Ксилометазолин de:Xylometazolin hu:Xylometazolin nl:Xylometazoline fi:Ksylometatsoliini

Template:WikiDoc Sources